Correlation Between Pfizer and Entrada Therapeutics

Can any of the company-specific risk be diversified away by investing in both Pfizer and Entrada Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pfizer and Entrada Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pfizer Inc and Entrada Therapeutics, you can compare the effects of market volatilities on Pfizer and Entrada Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pfizer with a short position of Entrada Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pfizer and Entrada Therapeutics.

Diversification Opportunities for Pfizer and Entrada Therapeutics

0.15

Correlation Coefficient

Pfizer  Entrada Therapeutics

Average diversification

The 3 months correlation between Pfizer and Entrada is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Pfizer Inc and Entrada Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entrada Therapeutics and Pfizer is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pfizer Inc are associated (or correlated) with Entrada Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entrada Therapeutics has no effect on the direction of Pfizer i.e., Pfizer and Entrada Therapeutics go up and down completely randomly.

Pair Corralation between Pfizer and Entrada Therapeutics

Considering the 90-day investment horizon Pfizer Inc is expected to generate 0.35 times more return on investment than Entrada Therapeutics. However, Pfizer Inc is 2.82 times less risky than Entrada Therapeutics. It trades about -0.05 of its potential returns per unit of risk. Entrada Therapeutics is currently generating about -0.27 per unit of risk. If you would invest  2,599  in Pfizer Inc on December 29, 2024 and sell it today you would lose (98.00) from holding Pfizer Inc or give up 3.77% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Pfizer Inc  vs.  Entrada Therapeutics

Pfizer Inc

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pfizer Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical and fundamental indicators, Pfizer is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders.

Entrada Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Entrada Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Pfizer and Entrada Therapeutics

The main advantage of trading using opposite Pfizer and Entrada Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pfizer position performs unexpectedly, Entrada Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entrada Therapeutics will offset losses from the drop in Entrada Therapeutics' long position.

The idea behind Pfizer Inc and Entrada Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.